Clinical Trial Update: AScalate: Treat-to-target in Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update for AScalate in axial spondyloarthritis: the study completed and results were posted. Sponsored by Novartis Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Axial Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2025-04-16